Polar Capital Global Healthcare Trust plc (PCGH)

Overview

Polar Capital Global Healthcare Trust plc is a UK-listed closed-ended investment company that commenced operations in June 2010. The trust is committed to achieving long-term capital growth by maintaining a diversified global portfolio specifically within the healthcare sector. This focus involves investing in various areas such as pharmaceuticals, biotechnology, medical devices, and healthcare services. The company strategically places its investments across multiple geographic regions, including the United States, Europe, and emerging markets such as India and Japan.

One of the defining characteristics of the trust is its concentrated portfolio, which typically comprises around 37 equity holdings. The trust’s top 10 positions, including well-known companies like Eli Lilly, AstraZeneca, and Thermo Fisher Scientific, generally represent over 40% of its total assets. This approach allows the trust to emphasize innovative growth stories that are pivotal to the evolution of the healthcare industry.

Additionally, the trust offers semi-annual dividends with a modest yield ranging between 0.5% and 0.6%. The ongoing charge associated with the trust is approximately 0.91%, and it employs no gearing. Its market trading occurs at a variable premium or discount relative to its net asset value, while benchmarking against the MSCI ACWI Health Care index. The trust plays a crucial role in providing investors with targeted exposure to the dynamic and rapidly evolving global healthcare industry, which is essential in fostering advancements in medical technologies and treatment options.

Products and Services

• Equity Investments

  The core product of Polar Capital Global Healthcare Trust plc revolves around equity investments in a diversified selection of healthcare-related companies. These investments include major sectors such as pharmaceuticals, biotechnology firms, medical device manufacturers, and healthcare service providers. By selecting innovative companies with promising growth prospects, the trust aims to deliver long-term capital appreciation to its investors.

• Portfolio Concentration

  The trust typically manages a concentrated portfolio consisting of around 37 equity holdings. This focused strategy allows the trust to invest significantly in its top positions, which include leading healthcare companies that are essential to advancing medical technologies and treatments. By concentrating assets, the trust is positioned to capitalize on high-impact growth opportunities within the healthcare sector.

• Dividends

  Polar Capital offers semi-annual dividends with a yield of approximately 0.5% to 0.6%. This feature provides a steady income stream for investors while they benefit from potential capital growth through the trust’s equity investments. The semi-annual nature of the dividends allows investors to enjoy regular distributions.

• Geographic Diversification

  Investments are strategically diversified across a global spectrum, covering regions such as the United States, Europe, and emerging markets like India and Japan. This geographic diversification mitigates risks associated with market fluctuations in any single region and allows the trust to capitalize on global healthcare advancement.

• Benchmarking

  The trust benchmarks itself against the MSCI ACWI Health Care index, providing investors with a reference point to evaluate performance. This performance measure aids in assessing how well the trust is meeting its objective of generating long-term capital growth relative to the broader healthcare sector.